白蛋白/干扰素α2b多剂量的单次和多次给药在慢性乙型肝炎患者中的耐受性、药代动力学和药效学临床试验
[Translation] Clinical trial on tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of albumin/interferon α2b in patients with chronic hepatitis B
为了考察本品在慢性乙型肝炎患者中单次、多次给药的安全性和耐受性以及药代动力学和药效学指标,并探索其治疗慢性乙型肝炎的初步临床疗效。
[Translation] To investigate the safety and tolerability of single and multiple doses of this product as well as its pharmacokinetic and pharmacodynamic indicators in patients with chronic hepatitis B, and to explore its preliminary clinical efficacy in the treatment of chronic hepatitis B.
注射用重组人血清白蛋白/干扰素α2b融合蛋白在健康成年志愿者中单次给药剂量递增I期临床试验
[Translation] Phase I clinical trial of single-dose escalation of recombinant human serum albumin/interferon α2b fusion protein for injection in healthy adult volunteers
考察本品在健康受试者中的安全性、耐受性以及药代动力学和药效学指标
[Translation] To investigate the safety, tolerability, pharmacokinetic and pharmacodynamic indicators of this product in healthy subjects
/ Not yet recruitingPhase 1 注射用重组人血清白蛋白/促红素融合蛋白单次给药、剂量递增的耐受性、安全性、药代动力学和药效学临床试验
[Translation] Clinical trial on the tolerability, safety, pharmacokinetics and pharmacodynamics of single-dose and dose-escalation recombinant human serum albumin/erythropoietin fusion protein for injection
(1) 评价rHSA/EPO对健康受试者的安全性和耐受性; (2) 考察rHSA/EPO在健康受试者体内的药代动力学特性,获取初步药代动力学参数。
[Translation] (1) To evaluate the safety and tolerability of rHSA/EPO in healthy subjects; (2) To investigate the pharmacokinetic properties of rHSA/EPO in healthy subjects and obtain preliminary pharmacokinetic parameters.
100 Clinical Results associated with Tianjin Linda Biotechnology Co Ltd
0 Patents (Medical) associated with Tianjin Linda Biotechnology Co Ltd
100 Deals associated with Tianjin Linda Biotechnology Co Ltd
100 Translational Medicine associated with Tianjin Linda Biotechnology Co Ltd